Pharma BD Deal Intelligence
Nektar's $32M buy of Aerogen to add liquid-inhalation tech to its pulmonary platform unwound in just over two years—management bought Aerogen back in a 2008 restructuring that saw Nektar exit devices entirely and sell the remaining pulmonary business to Novartis for $115M. Aerogen later thrived independently, but that upside never returned to Nektar.
Nektar bought Aerogen to broaden pulmonary delivery, then spun it back out via management buyout just over two years later — a strategic reversal, not a value-creating hold.
Full analysis, sources & comparables →Aerogen had commercialized its Aeroneb Micropump Nebulizer products for hospital, home and pre-clinical use through a network of world-class respiratory…
The acquisition broadens Nektar's pulmonary delivery capabilities by adding advanced inhaleable liquid drug technology to Nektar's base of leading inhaleable…
Nektar Therapeutics announced today that it has closed the acquisition of Aerogen, Inc., following stockholder approval on October 19, 2005.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Nektar agrees to acquire Aerogen (~$32M; $8M cash + $24M stock) for inhaled-liquid pulmonary technology. Closed October 2005.
Nektar bought Aerogen to broaden pulmonary delivery, then spun it back out via management buyout just over two years later — a strategic reversal, not a value-creating hold.
Assessment window: 15yr post-close.
Aerogen developed inhaled-liquid drug delivery devices (the OnQ Aerosol Generator / AeroDose platform) for respiratory disorders treated in the acute care setting — including ventilated ICU patients and patients requiring nebulized antibiotics, bronchodilators, and surfactants. The platform addressed limitations of conventional jet nebulizers (low lung deposition, long treatment times, drug waste).
Inhaled drug delivery in 2005 was bifurcated: dry-powder leaders Nektar (Exubera inhaled insulin partner with Pfizer), Vectura, Alkermes (AIR), and 3M competed for systemic delivery, while liquid nebulization was dominated by PARI (LC PLUS jet nebulizer) and Aradigm's AERx. Aerogen's vibrating-mesh OnQ platform demonstrated ~3x higher lung deposition versus PARI LC PLUS at half the treatment time in cystic fibrosis tobramycin studies (PubMed 12527599). Nektar's $32M acquisition (~$8M cash + ~$24M stock per Outsourcing-Pharma and SEC 425 filings) extended its powder-only portfolio into liquids, broadened its IP estate by 35+ patents, and added an acute-care channel adjacent to its Tobi/Cipro inhalation collaborations. The deal positioned Nektar against Novartis (which later acquired Chiron's Tobi franchise) and against emerging mesh-nebulizer player PARI eFlow. Aerogen's neonatal/ICU programs survived the acquisition and were spun back out in 2008 as Aerogen Ltd. (Galway, Ireland), which remains active in critical-care inhalation today. Source: https://www.outsourcing-pharma.com/Article/2005/08/16/Nektar-buys-Aerogen-to-expand-into-inhaleable-liquids
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nektar Therapeutics / Aerogen, Inc. (this deal) | 2005 | $32M | 27 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
| Reckitt Benckiser plc / Boots Healthcare International | 2005 | $3.4B | 78 |
← Browse all deals · How we score deals
More: 2005 deals